Base de dados : MEDLINE
Pesquisa : D02.065.589.099.750.750.050.500 [Categoria DeCS]
Referências encontradas : 639 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 64 ir para página                         

  1 / 639 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18309164
[Au] Autor:Schwarz S; Al-Shajlawi F; Sick C; Meairs S; Hennerici MG
[Ad] Endereço:Departments of Neurology, Klinikum Mannheim, University of Heidelberg, Mannheim, Germany. stefan.schwarz@zi-mannheim.de
[Ti] Título:Effects of prophylactic antibiotic therapy with mezlocillin plus sulbactam on the incidence and height of fever after severe acute ischemic stroke: the Mannheim infection in stroke study (MISS).
[So] Source:Stroke;39(4):1220-7, 2008 Apr.
[Is] ISSN:1524-4628
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: Fever after stroke is a strong predictor for a negative outcome with infections as the most common cause. The aim of this pilot study was to evaluate the effects of prophylactic antibiotic therapy on the incidence and height of fever after acute ischemic stroke. METHODS: This is a randomized, controlled study of antibiotic prophylaxis in patients with ischemic stroke enrolled within 24 hours from clinical onset who presented bedridden (modified Rankin score >3) with no significant infection. Interventions included prophylactic mezlocillin plus sulbactam (3 x 2 g/1 g for 4 days) or conventional management. Over 10 days, body temperature was continuously monitored, and the presence of infection was daily assessed. Primary end points were incidence and height of fever; secondary end points included rate of infection and clinical outcome. RESULTS: Sixty patients were included (mean, 75 years; median National Institutes of Health Stroke Scale score, 16). Over the first 3 days, patients in the intervention group showed lower mean body temperatures as well as lower daily peak temperatures (P<0.05). Throughout the observation period, 15 of 30 patients in the intervention group but 27 of 30 patients in the conventionally treated group developed an infection (P<0.05). Mean interval until the diagnosis of infection was 5.1 days in the intervention group and 3.3 days in the control group (P<0.05). Clinical outcome was more favorable in patients with prophylactic therapy (P=0.01). CONCLUSIONS: In patients with acute severe stroke, prophylactic administration of mezlocillin plus sulbactam over 4 days decreases body temperature, lowers the rate of infection, and may be associated with a better clinical outcome.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Isquemia Encefálica/tratamento farmacológico
Febre/prevenção & controle
Mezlocilina/administração & dosagem
Acidente Vascular Cerebral/tratamento farmacológico
Sulbactam/administração & dosagem
[Mh] Termos MeSH secundário: Doença Aguda
Idoso
Idoso de 80 Anos ou mais
Infecções Bacterianas/epidemiologia
Infecções Bacterianas/prevenção & controle
Isquemia Encefálica/epidemiologia
Quimioterapia Combinada
Feminino
Febre/epidemiologia
Seres Humanos
Incidência
Masculino
Meia-Idade
Projetos Piloto
Prognóstico
Índice de Gravidade de Doença
Acidente Vascular Cerebral/epidemiologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); OH2O403D1G (Mezlocillin); S4TF6I2330 (Sulbactam)
[Em] Mês de entrada:0804
[Cu] Atualização por classe:161122
[Lr] Data última revisão:
161122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080301
[St] Status:MEDLINE
[do] DOI:10.1161/STROKEAHA.107.499533


  2 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16602839
[Au] Autor:August Fuhr N; Becker C; van Baalen A; Bauer K; Hopp H
[Ad] Endereço:Department of Obstetrics and Gynecology, Campus Benjamin Franklin, Charite Berlin, Germany. norbertaugust.fuhr@charite.de
[Ti] Título:Antibiotic therapy for preterm premature rupture of membranes - results of a multicenter study.
[So] Source:J Perinat Med;34(3):203-6, 2006.
[Is] ISSN:0300-5577
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:AIMS: To evaluate whether primary application of mezlozillin in preterm premature rupture of membranes (pPROM) prolongs pregnancy and lowers neonatal morbidity. METHODS: In this prospective, randomized, double blind, placebo-controlled multicenter study a total of 105 pregnant women with pPROM between 24 + 0 and 32 + 6 weeks of gestation were examined receiving i.v. injections of corticoids and tocolytics as well as mezlocillin (3 x 2 g/d) or placebo. Assessed factors were prolongation of pregnancy and neonatal morbidity such as neonatal infection, respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC). RESULTS: Prolongation of pregnancy by more than 7 days was achieved in 63.8% of the mezlocillin group versus 44.8% of the placebo group (P < 0.05). The babies of mothers treated with anibiotics had fewer neonatal infections, RDS, IVH and NEC. Total morbidity was significantly lowered in the verum group (P = 0.02). CONCLUSIONS: Antibiotic administration following preterm premature rupture of membranes is associated with a prolongation of pregnancy and a reduction of neonatal infectious morbidity.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Ruptura Prematura de Membranas Fetais/tratamento farmacológico
Mezlocilina/uso terapêutico
[Mh] Termos MeSH secundário: Infecções Bacterianas/epidemiologia
Infecções Bacterianas/prevenção & controle
Hemorragia Cerebral/epidemiologia
Método Duplo-Cego
Enterocolite Necrosante/epidemiologia
Feminino
Seres Humanos
Recém-Nascido
Doenças do Recém-Nascido/epidemiologia
Doenças do Recém-Nascido/prevenção & controle
Gravidez
Resultado da Gravidez
Estudos Prospectivos
Síndrome do Desconforto Respiratório do Recém-Nascido/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); OH2O403D1G (Mezlocillin)
[Em] Mês de entrada:0610
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060411
[St] Status:MEDLINE


  3 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11953060
[Au] Autor:Li C; Zeng W; Chen Y
[Ad] Endereço:Department of Obstetrics and Gynecology, The Second Huaxi Hospital of Sichuan University, Chengdu 610041, China.
[Ti] Título:[Analysis of prophylactic antibiotics for cesarean section].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;37(1):25-6, 2002 Jan.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To study the appropriate antibiotic for prophylactic use in cesarean section. METHODS: The effects and side effects of prophylatic antibiotics in 1 266 cesarean section were studied retrospectively. Six regiems were engaged: (1) Penicillin and Ampicillin; (2) Mezlocillin sodium; (3) Sulbactam and Ampicillin; (4) Ciprofloxacin; (5) Clindamycin; (6) Cefacidal. RESULTS: The duration of postoperative body temperature return to normal of 1 - 6 group is (54.0 +/- 28.4) hours, (48.9 +/- 27.8) hours, (49.9 +/- 23.9) hours, (58.6 +/- 33.7) hours, (52.5 +/- 25.2) hours, (63.1 +/- 51.1) hours respectively. It was longer in cefazolin group than the others. There were less puerperal morbidity and side effects of Mezlocillin. CONCLUSIONS: Penicillin and Ampicillin are still the most common choices as prophylatic antibiotic in cesarean section. Mezlocillin is appropriate as well.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Infecção da Ferida Cirúrgica/prevenção & controle
[Mh] Termos MeSH secundário: Ampicilina/uso terapêutico
Antibioticoprofilaxia
Cesárea
Quimioterapia Combinada
Feminino
Seres Humanos
Mezlocilina/uso terapêutico
Penicilinas/uso terapêutico
Estudos Retrospectivos
Sulbactam/uso terapêutico
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Penicillins); 7C782967RD (Ampicillin); OH2O403D1G (Mezlocillin); S4TF6I2330 (Sulbactam)
[Em] Mês de entrada:0206
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:020416
[St] Status:MEDLINE


  4 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11880954
[Au] Autor:Ehrenstein BP; Salamon L; Linde HJ; Messmann H; Schölmerich J; Glück T
[Ad] Endereço:Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität, 93042 Regensburg, Germany. Boris.Ehrenstein@klinik.uni-r.de
[Ti] Título:Clinical determinants for the recovery of fungal and mezlocillin-resistant pathogens from bile specimens.
[So] Source:Clin Infect Dis;34(7):902-8, 2002 Apr 01.
[Is] ISSN:1537-6591
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We conducted a retrospective analysis of all bile specimens obtained for routine cultures from January 1995 through December 1999 at our tertiary care hospital. Results of microbiologic testing were linked to clinical parameters gathered by means of chart review. A total of 722 isolates were cultured from 345 of 454 bile specimens obtained from 288 individual patients. Prior receipt of a >7-day course of antibiotics (odds ratio [OR], 5.7), extensive leukocytosis (leukocyte count, >20,000 cells/microL) on admission (OR, 7.8), endoscopic or percutaneous biliary manipulation during the previous 14 days (OR, 2.9), and treatment in an internal medicine ward (OR, 2.5) were independent factors significantly associated (Pless-than-or-eq, slant.05) with recovery of Candida species from bile specimens. Culture of mezlocillin-resistant bacteria from bile specimens was independently associated with the specimen having been obtained >1 week after admission (OR, 3.8), lack of history of endoscopic biliary drainage (OR, 3.2), and high serum aspartate aminotransferase levels (>72 U/L) on admission (OR, 2.6). Prospective studies are warranted to evaluate accordingly adjusted empiric therapies for biliary infections.
[Mh] Termos MeSH primário: Doenças dos Ductos Biliares/diagnóstico
Candidíase/diagnóstico
[Mh] Termos MeSH secundário: Bactérias/efeitos dos fármacos
Doenças dos Ductos Biliares/tratamento farmacológico
Doenças dos Ductos Biliares/microbiologia
Candida/efeitos dos fármacos
Candidíase/tratamento farmacológico
Resistência Microbiana a Medicamentos
Seres Humanos
Mezlocilina/farmacologia
Testes de Sensibilidade Microbiana
Penicilinas/farmacologia
Penicilinas/uso terapêutico
Prognóstico
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Penicillins); OH2O403D1G (Mezlocillin)
[Em] Mês de entrada:0203
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:020307
[St] Status:MEDLINE


  5 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11735011
[Au] Autor:Schwarz M; Isenmann R; Thomsen J; Gaus W; Beger HG
[Ad] Endereço:Department of General Surgery, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany.
[Ti] Título:Efficacy of oral ofloxacin for single-dose perioperative prophylaxis in general surgery--a controlled randomized clinical study.
[So] Source:Langenbecks Arch Surg;386(6):397-401, 2001 Nov.
[Is] ISSN:1435-2443
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Perioperative antibiotic prophylaxis surely reduces surgical infection rate. Pharmacokinetic data of oral ofloxacin in combination with its antibacterial spectrum suggest effective protection against perioperative infection. In addition, costs, adverse effects, and induction of microbial resistance are low. Therefore we performed a controlled randomized study comparing oral and intravenous single dose prophylaxis. METHODS: A total of 61 patients undergoing colonic or pancreatic resection randomly received either a single dose standard intravenous prophylaxis or ofloxacin 400 mg and metronidazole 500 mg orally 2 h before surgery. Postoperative infections were recorded for 3 weeks. RESULTS: Groups were very well comparable regarding age, overweight, concomitant disease, type and duration of surgery, blood loss, and volume support. Infectious complications occurred in 14.8% after parenteral and 3.3% after enteral antibiotic prophylaxis. There was no difference in post-operative hospital stay. CONCLUSION: The data demonstrate that single-dose oral ofloxacin is at least as effective as a standard intravenous prophylaxis in patients with colonic or pancreatic resection. It offers significant advantages regarding costs and ease of administration.
[Mh] Termos MeSH primário: Antibioticoprofilaxia
Ofloxacino/uso terapêutico
Infecção da Ferida Cirúrgica/prevenção & controle
[Mh] Termos MeSH secundário: Administração Oral
Anti-Infecciosos/administração & dosagem
Anti-Infecciosos/uso terapêutico
Colo/cirurgia
Feminino
Seres Humanos
Injeções Intravenosas
Masculino
Metronidazol/administração & dosagem
Metronidazol/uso terapêutico
Mezlocilina/administração & dosagem
Mezlocilina/uso terapêutico
Meia-Idade
Ofloxacino/administração & dosagem
Pâncreas/cirurgia
Infecção da Ferida Cirúrgica/epidemiologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Infective Agents); 140QMO216E (Metronidazole); A4P49JAZ9H (Ofloxacin); OH2O403D1G (Mezlocillin)
[Em] Mês de entrada:0201
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:011206
[St] Status:MEDLINE


  6 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11545485
[Au] Autor:Schwarz M; Isenmann R; Weikert E; Ebeling P; Thomsen J; Beger HG
[Ad] Endereço:Dept. of General Surgery, University of Ulm, Germany.
[Ti] Título:Pharmacokinetic basis for oral perioperative prophylaxis with ofloxacin in general surgery.
[So] Source:Infection;29(4):222-7, 2001 Aug.
[Is] ISSN:0300-8126
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Perioperative prophylaxis is recommended to be administered intravenously which, compared to oral prophylaxis, is more expensive. However, pharmacokinetic data on oral perioperative prophylaxis in patients with preoperative surgical and anesthesiological preparation are not available. PATIENTS AND METHODS: 40 patients with open hernial repair or cholecystectomy (low-risk group), colonic or pancreatic resection (high-risk group) received a standard single-dose perioperative prophylaxis with 4.5 g mezlocillin and 0.5 g metronidazole intravenously in addition to 400 mg ofloxacin orally 2 h prior to surgery. Antibiotic concentrations were measured perioperatively and pharmacokinetic data calculated. RESULTS: Serum and tissue concentrations of ofloxacin were above the MIC90 of the potential bacterial spectrum for surgical infection throughout the entire operation. Pharmacokinetic data were not influenced by preoperative surgical or anesthesiological preparation. CONCLUSION: Tissue and serum concentrations and the antibacterial spectrum of orally administered ofloxacin suggest effective protection against perioperative infection. Pharmacokinetic data confirm that oral ofloxacin may be used effectively as single-dose perioperative antibiotic prophylaxis. Since there are no clinical data comparing oral and intravenous singLe-dose prophylaxis, a prospective randomized clinical trial should be performed.
[Mh] Termos MeSH primário: Anti-Infecciosos/farmacocinética
Anti-Infecciosos/uso terapêutico
Antibioticoprofilaxia
Ofloxacino/farmacocinética
Ofloxacino/uso terapêutico
Cuidados Pré-Operatórios/métodos
[Mh] Termos MeSH secundário: Administração Oral
Anti-Infecciosos/administração & dosagem
Seres Humanos
Injeções Intravenosas
Metronidazol/farmacocinética
Metronidazol/uso terapêutico
Mezlocilina/farmacocinética
Mezlocilina/uso terapêutico
Ofloxacino/administração & dosagem
Penicilinas/farmacocinética
Penicilinas/uso terapêutico
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Penicillins); 140QMO216E (Metronidazole); A4P49JAZ9H (Ofloxacin); OH2O403D1G (Mezlocillin)
[Em] Mês de entrada:0202
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010908
[St] Status:MEDLINE


  7 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11282265
[Au] Autor:Hunfeld KP; Weigand J; Wichelhaus TA; Kekoukh E; Kraiczy P; Brade V
[Ad] Endereço:Institute of Medical Microbiology, University Hospital of Frankfurt, Paul-Ehrlich-Strasse 40, 60596 Frankfurt/Main, Germany. k.hunfeld@em.uni-frankfurt.de
[Ti] Título:In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi.
[So] Source:Int J Antimicrob Agents;17(3):203-8, 2001 Mar.
[Is] ISSN:0924-8579
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The in vitro susceptibility profile of Borrelia burgdorferi is not yet well defined for several antibiotics. Our study explored the in vitro susceptibility of B. burgdorferi to mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid. Minimal inhibitory concentrations (MICs) and minimal borreliacidal concentrations (MBCs) were measured using a standardised colorimetric microdilution method and conventional subculture experiments. MIC values were lowest for mezlocillin (MIC(90), < or =0.06 mg/l) and meropenem (MIC(90), 0.33 mg/l). Vancomycin (MIC(90), 0.83 mg/l) was less effective in vitro. Borreliae proved to be resistant to aztreonam (MIC(90), >32 mg/l), teicoplanin (MIC(90), 6.6 mg/l), ribostamycin (MIC(90), 32 mg/l), and fusidic acid (MIC(90), >4 mg/l). The mean MBCs resulting in 100% killing of the final inoculum after 72 h of incubation were lowest for mezlocillin (MBC, 0.83 mg/l). This study gathered further data on the in vitro susceptibility patterns of the B. burgdorferi complex. The excellent in vitro effectiveness of acylamino-penicillin derivatives and their suitability for the therapy of Lyme disease is emphasised.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Grupo Borrelia Burgdorferi/efeitos dos fármacos
[Mh] Termos MeSH secundário: Aztreonam/farmacologia
Resistência Microbiana a Medicamentos
Ácido Fusídico/farmacologia
Seres Humanos
Mezlocilina/farmacologia
Testes de Sensibilidade Microbiana
Monobactamas/farmacologia
Penicilinas/farmacologia
Ribostamicina/farmacologia
Teicoplanina/farmacologia
Tienamicinas/farmacologia
Vancomicina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Monobactams); 0 (Penicillins); 0 (Thienamycins); 2Q5JOU7T53 (Ribostamycin); 59XE10C19C (Fusidic Acid); 61036-62-2 (Teicoplanin); 6Q205EH1VU (Vancomycin); FV9J3JU8B1 (meropenem); G2B4VE5GH8 (Aztreonam); OH2O403D1G (Mezlocillin)
[Em] Mês de entrada:0105
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010403
[St] Status:MEDLINE


  8 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:11083642
[Au] Autor:DeLoney CR; Schiller NL
[Ad] Endereço:Division of Biomedical Sciences, University of California, Riverside, Riverside, California 92521, USA.
[Ti] Título:Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori.
[So] Source:Antimicrob Agents Chemother;44(12):3368-73, 2000 Dec.
[Is] ISSN:0066-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An amoxicillin-resistant (Amox(r)) strain of Helicobacter pylori was selected for by culturing an amoxicillin-sensitive (Amox(s)) strain in increasingly higher concentrations of amoxicillin, resulting in a 133-fold increase in MIC, from 0.03 to 0.06 microg/ml to 4 to 8 microg/ml. This resistance was stable upon freezing for at least 6 months and conferred cross-resistance to seven other beta-lactam antibiotics. beta-Lactamase activity was not detected in this Amox(r) strain; however, analysis of the penicillin-binding protein (PBP) profiles generated from isolated bacterial membranes of the Amox(s) parental strain and the Amox(r) strain revealed a significant decrease in labeling of PBP 1 by biotinylated amoxicillin (bio-Amox) in the Amox(r) strain. Comparative binding studies of PBP 1 for several beta-lactams demonstrated that PBP 1 in the Amox(r) strain had decreased affinity for mezlocillin but not significantly decreased affinity for penicillin G. In addition, PBP profiles prepared from whole bacterial cells showed decreased labeling of PBP 1 and PBP 2 in the Amox(r) strain at all bio-Amox concentrations tested, suggesting a diffusional barrier to bio-Amox or a possible antibiotic efflux mechanism. Uptake analysis of (14)C-labeled penicillin G showed a significant decrease in uptake of the labeled antibiotic by the Amox(r) strain compared to the Amox(s) strain, which was not affected by pretreatment with carbonyl cyanide m-chlorophenylhydrazone, eliminating the possibility of an efflux mechanism in the resistant strain. These results demonstrate that alterations in PBP 1 and in the uptake of beta-lactam antibiotics in H. pylori can be selected for by prolonged exposure to amoxicillin, resulting in increased resistance to this antibiotic.
[Mh] Termos MeSH primário: Amoxicilina/farmacologia
Proteínas de Bactérias
Resistência a Múltiplos Medicamentos/fisiologia
Helicobacter pylori/metabolismo
Hexosiltransferases
Resistência às Penicilinas/fisiologia
Peptidil Transferases
[Mh] Termos MeSH secundário: Radioisótopos de Carbono
Proteínas de Transporte/metabolismo
Reações Cruzadas
Helicobacter pylori/efeitos dos fármacos
Helicobacter pylori/enzimologia
Seres Humanos
Mezlocilina/farmacologia
Muramilpentapeptídeo Carboxipeptidase/metabolismo
Penicilina G/farmacologia
Proteínas de Ligação às Penicilinas
Resistência beta-Lactâmica/fisiologia
beta-Lactamases/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Carbon Radioisotopes); 0 (Carrier Proteins); 0 (Penicillin-Binding Proteins); 804826J2HU (Amoxicillin); EC 2.3.2.12 (Peptidyl Transferases); EC 2.4.1.- (Hexosyltransferases); EC 3.4.17.8 (Muramoylpentapeptide Carboxypeptidase); EC 3.5.2.6 (beta-Lactamases); OH2O403D1G (Mezlocillin); Q42T66VG0C (Penicillin G)
[Em] Mês de entrada:0102
[Cu] Atualização por classe:170219
[Lr] Data última revisão:
170219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:001118
[St] Status:MEDLINE


  9 / 639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10381111
[Au] Autor:Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
[Ad] Endereço:Servicio de Microbiología Clínica, Hospital Clínico San Carlos, Madrid, Spain. cbetriu@efd.net
[Ti] Título:In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
[So] Source:J Antimicrob Chemother;43(1):133-6, 1999 Jan.
[Is] ISSN:0305-7453
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The in-vitro activities of imipenem and four beta-lactam-beta-lactamase inhibitor combinations were tested against 816 strains of the Bacteroides fragilis group, and compared with other anti-anaerobic agents. None of the strains was resistant to metronidazole, and only one was resistant to chloramphenicol. Mezlocillin and piperacillin were moderately active, while clindamycin was the least active. Rates of resistance varied between various species. The new beta-lactam agents tested showed excellent activity; piperacillin-tazobactam and imipenem were the most active. The emergence of strains that are resistant to these agents, observed in this study, suggests there is a need to perform periodic antimicrobial susceptibility tests.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Bacteroides fragilis/efeitos dos fármacos
[Mh] Termos MeSH secundário: Amoxicilina/farmacologia
Ampicilina/farmacologia
Cefoxitina/farmacologia
Ceftizoxima/farmacologia
Cloranfenicol/farmacologia
Ácido Clavulânico/farmacologia
Clindamicina/farmacologia
Quimioterapia Combinada
Inibidores Enzimáticos/farmacologia
Imipenem/farmacologia
Metronidazol/farmacologia
Mezlocilina/farmacologia
Testes de Sensibilidade Microbiana
Ácido Penicilânico/análogos & derivados
Ácido Penicilânico/farmacologia
Penicilinas/farmacologia
Piperacilina/farmacologia
Especificidade da Espécie
Sulbactam/farmacologia
Tienamicinas/farmacologia
Ticarcilina/farmacologia
Inibidores de beta-Lactamases
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Enzyme Inhibitors); 0 (Penicillins); 0 (Thienamycins); 0 (beta-Lactamase Inhibitors); 140QMO216E (Metronidazole); 23521W1S24 (Clavulanic Acid); 3U02EL437C (Clindamycin); 66974FR9Q1 (Chloramphenicol); 6OEV9DX57Y (Cefoxitin); 71OTZ9ZE0A (Imipenem); 7C782967RD (Ampicillin); 804826J2HU (Amoxicillin); 87-53-6 (Penicillanic Acid); C43C467DPE (Ceftizoxime); F93UJX4SWT (Ticarcillin); OH2O403D1G (Mezlocillin); S4TF6I2330 (Sulbactam); SE10G96M8W (tazobactam); X00B0D5O0E (Piperacillin)
[Em] Mês de entrada:9910
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990625
[St] Status:MEDLINE


  10 / 639 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:10192476
[Au] Autor:Guariglia L; Conte M; Are P; Rosati P
[Ad] Endereço:Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
[Ti] Título:Ultrasound-guided fine needle aspiration of ovarian cysts during pregnancy.
[So] Source:Eur J Obstet Gynecol Reprod Biol;82(1):5-9, 1999 Jan.
[Is] ISSN:0301-2115
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the safety and efficacy of ultrasound-guided fine needle aspiration in the treatment of ovarian cysts during pregnancy. STUDY DESIGN: Nine out of twenty-nine patients between the 6th and the 16th week of gestation with unilateral ovarian cysts ranging between 65 and 540 cm3 in volume were selected for sonographically-guided fine needle aspiration. RESULTS: No complications were observed at either short or long-term follow-up; all patients delivered healthy infants at term. Clinical and sonographic post-partum follow-up was uneventful in all cases. In three cases it was necessary to repeat the procedure once and in one case twice during pregnancy. In one case a recurrent serous cyst was excised at operative laparoscopy performed 3 months after delivery. CONCLUSIONS: Ultrasound-guided fine needle aspiration was safely performed in nine patients as an alternative treatment to surgery when persistent monolateral and unilocular ovarian cysts with regular borders and completely anechoic structure are detected during pregnancy.
[Mh] Termos MeSH primário: Cistos Ovarianos/cirurgia
Ovário/patologia
Complicações na Gravidez/cirurgia
[Mh] Termos MeSH secundário: Adulto
Biópsia por Agulha/métodos
Feminino
Seres Humanos
Mezlocilina/uso terapêutico
Cistos Ovarianos/diagnóstico por imagem
Ovário/diagnóstico por imagem
Penicilinas/uso terapêutico
Gravidez
Complicações na Gravidez/diagnóstico por imagem
Resultado da Gravidez
Primeiro Trimestre da Gravidez
Segundo Trimestre da Gravidez
Progesterona/uso terapêutico
Recidiva
Sucção
Ultrassonografia Pré-Natal
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Penicillins); 4G7DS2Q64Y (Progesterone); OH2O403D1G (Mezlocillin)
[Em] Mês de entrada:9906
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990407
[St] Status:MEDLINE



página 1 de 64 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde